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Introduction
Intra-articular corticosteroid injections (IACI) are a
standard treatment in juvenile idiopathic arthritis (JIA).
Objectives
This study aims to assess the use and response to IACI in
a large prospective cohort of children and young people
(CYP) recruited at initiation of treatment for JIA.
Methods
Participants were in the Childhood Arthritis Prospective
Study (CAPS), an on-going prospective inception cohort
study in 7 UK paediatric rheumatology centres. The aim
of CAPS is to provide long-term outcome data on CYP
with new-onset inflammatory arthritis receiving specialist
care. CAPS recruits CYP <16 years with new inflammatory
arthritis persisting for ≥ 2 weeks. Demographics, disease
features, joint count, treatment details, Childhood Health
Assessment Questionnaire (CHAQ), physician’s global
assessment (PGA), parent’s general evaluation of well-
being (PGE), ESR are collected at first presentation, 6
months, then yearly.
Results
Of the 1477 CYP recruited to CAPS 759 have completed
3 years follow-up. 603 (79.5%) were treated with intra-
articular cortico-steroid injections. 185 (24.4%) patients
required IACI alone (with a single episode of injection
as the only treatment in 100, (13 % of the total cohort)
usually the knee in 80 %. The majority of injected
patients went on to receive additional treatments, 393
(69.3%) commenced a disease-modifying anti-rheumatic
drug or biologic agent. Of these, 93 patients received
both DMARD/ biologic and IACI at the same time. No
IACIs were received in 156 patients (20.55%) with 71 of
these patients receiving oral or intra-venous steroids, 88
DMARDs and 27 biologic drugs.
Of the 185 patients treated only with IACI, 85 had more
than one episode of injections. For this group the median
time to first injection was 14 days (IQR 6.36) and time
from first to second injection was 318 days ( IQR 162-525)
illustrating a prolonged effect from the first injection.
390 of the 759 patients completing 3 years of follow-up
had oligoarticular JIA of whom 332 (85%) received ster-
oid injections, 163 (42%) treated exclusively with IACI 85
(25%) receiving only one episode of injection.Baseline
predictors of the need for DMARD in addition to IACI
were a higher total active and limited joint counts, ESR,
physician’s global and the CHAQ score (p<0.0001), and
pain scores (p<0.003).
Conclusion
The data confirms that most children with JIA receive
IACI usually in conjunction with other therapies. Approxi-
mately one quarter of patients required monotherapy with
IACI alone. 13% of all patients and 25% of oligo-articular
course patients were managed with a single injection
alone. Higher measures of disease activity were signifi-
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